4-acetamidophenyl sulfamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-acetamidophenyl sulfamate
• 英文别名: N-[4-[(Aminosulfonyl)oxy]phenyl]acetamide；sulfamic acid 4-(acetylamino)phenyl ester；(4-acetamidophenyl) sulfamate
• 化学式: C₈H₁₀N₂O₄S
• 分子量: 230.244
• InChiKey: ALXUQOFCHVUEPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  对乙酰氨基酚 在 N-甲基咪唑 、 pentachlorophenyl sulfamate 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以75%的产率得到4-acetamidophenyl sulfamate
  参考文献：
  名称：

  活化的芳基氨基磺酸盐对醇的催化氨磺酰化反应。

  摘要：

  我们报告了一种新的乙醇氨磺酰化催化方法，该方法将缺乏电子的芳基氨基磺酸盐用作活化基团转移试剂。该反应利用简单的有机碱N-甲基咪唑，在温和的条件下进行，并提供1°超过2°的醇的固有选择性（某些核苷最高> 40：1）。必需的氨基磺酸芳基酯供体是稳定的结晶固体，可以容易地大规模制备。机理上的考虑支持了HNSO2“氮杂亚砜”在转移反应中的中介作用。

  DOI：

  10.1021/acs.orglett.9b04119

文献信息

• Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
  申请人：A. H. Robins Co., Inc.

  公开号：US05025031A1

  公开（公告）日：1991-06-18

  Herein disclosed is a method of treating convulsions with a pharmaceutical composition containing a compound of the formula: (HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z where A is an aryl, arylalkyl, or aryloxyalkyl group and is substituted on 1 or more carbon atoms with a sulfamate group (--OSO.sub.2 NR.sup.1 R.sup.2) wherein R.sup.1 and R.sup.2, same or different, are hydrogen or loweralkyl wherein p is 0 or 1 and is the number of untreated hydroxyl groups and z is 1 or 2 and is the number of --OS(O.sub.2)NR.sup.1 R.sup.2 groups. Aryl is selected from phenyl, substituted phenyl, pyridinyl, naphthyl, quinolinyl, and the like. Phenyl substituents are selected from hydrogen, halo, hydroxy, phenyl, phenoxy, benzoyl, loweralkyl, loweralkoxy, carboxy, amino, loweralkylamino, diloweralkylamino, acetamido, cyano, nitro, loweralkoxycarboyl, aminosulfonyl, imidazolyl, triazolyl, and the like. Novel compounds not previously disclosed are also described.

  以下披露了一种使用含有化合物的药物组合物来治疗惊厥的方法：(HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z，其中A是芳基、芳基烷基或芳氧烷基基团，并在1个或多个碳原子上用磺酰胺基团(--OSO.sub.2 NR.sup.1 R.sup.2)取代，其中R.sup.1和R.sup.2，相同或不同，是氢或较低烷基，其中p为0或1，是未处理的羟基团的数量，z为1或2，是--OS(O.sub.2)NR.sup.1 R.sup.2基团的数量。芳基选自苯基、取代苯基、吡啶基、萘基、喹啉基等。苯基取代基选自氢、卤素、羟基、苯基、苯氧基、苯甲酰基、较低烷基、较低烷氧基、羧基、氨基、较低烷基氨基、二较低烷基氨基、乙酰胺基、氰基、硝基、较低烷氧羰基、氨基磺酰基、咪唑基、三唑基等。还描述了以前未披露的新化合物。
• Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors
  作者：Jean-Yves Winum、Daniela Vullo、Angela Casini、Jean-Louis Montero、Andrea Scozzafava、Claudiu T. Supuran

  DOI：10.1021/jm021124k

  日期：2003.5.1

  (steroidal), and sugar moieties in their molecules has been synthesized and assayed as inhibitors of the zinc enzyme carbonic anhydrase (CA), and more precisely of the cytosolic isozymes CA I andII, and the transmembrane, tumor-associated isozymes CA IX. Some of these compounds were previously reported to act as inhibitors of steroid sulfatases, among which estrone sulfatase (ES) and dehydroepiandrosterone

  已经合成了一系列在分子中结合了脂肪族，芳香族，多环（甾族）和糖基团的氨基磺酸盐或双氨基磺酸盐，并将其检测为锌酶碳酸酐酶（CA），更确切地说是胞质同工酶CA I的抑制剂。和II，以及跨膜，与肿瘤相关的同工酶CA IX。这些化合物中的某些以前据报道可充当甾族硫酸酯酶的抑制剂，其中雌酮硫酸酯酶（ES）和脱氢表雄甾酮硫酸酯酶（DHEAS）是雌激素依赖性肿瘤的关键治疗靶标。针对三种研究的CA同工酶，检测到非常有效的（纳摩尔量）抑制剂。最好的CA I抑制剂是苯氨基磺酸盐及其某些4-卤代衍生物，以及脂肪族化合物正辛基氨基磺酸盐。针对CA II，低纳摩尔抑制剂（1。1-5 nM）是苯氨基磺酸盐及其一些4-卤代/硝基衍生物，正辛基氨基磺酸盐和雌二醇3,17β-二氨基磺酸盐等。所有研究的氨基磺酸盐均显示出有效的CA IX抑制特性，抑制常数在18-63 nM的范围内。到目前为止，检测到的最好的CA IX抑制剂是
• Sulfamates as antiglaucoma agents
  申请人：A. H. Robins Company, Incorporated

  公开号：US05192785A1

  公开（公告）日：1993-03-09

  Sulfamate esters of the formula (HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z where A is aryloxyalkyl, p is the number of unreacted hydroxy groups present on the alkyl moiety and may be zero, z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups attached to carbons of the alkyl moiety and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy, and the like are useful in treating glaucoma.

  公式为(HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.z的磺酰胺酯，其中A为芳氧基烷基，p是烷基部分未反应的羟基数，可以为零，z为连接到烷基部分碳上的--OS(O).sub.2 NR.sup.1 R.sup.2基团数，且始终至少为1；R.sup.1和R.sup.2从氢、低碳基、羧基等中选择，可用于治疗青光眼。
• Compounds having one or more aminosulfaonyloxy radicals useful as
  申请人：A. H. Robins Company, Incorporated

  公开号：US05194446A1

  公开（公告）日：1993-03-16

  Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula: (HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z wherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

  使用已知和新颖化合物治疗慢性关节炎和骨质疏松的方法，这些化合物可以归纳为以下一般公式：（HO）p-A-[-OS（O）2 NR1R2] z，其中A包括广泛的值，包括但不限于芳香族，低烷基，环烷基和碳水化合物，包括蔗糖和果糖；p等于分子中未反应的羟基数，可以为零；z是-OS（O）2 NR1R2基团的数量，始终至少为一；R1和R2从氢，低烷基，羧基等中选择；提供了一种新颖的制备该化合物的方法，其中适当的磺酸芳基酯与含有保护的羧基，氨基或羟基取代基的羟基取代的A基团在含有三级胺碱的无极溶剂中反应。还提供了用于治疗慢性关节炎和骨质疏松的制药组合物。
• Compounds having one or more aminosulfonyloxy radicals useful as
  申请人：A. H. Robins Company, Incorporated

  公开号：US05273993A1

  公开（公告）日：1993-12-28

  Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula: (HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z wherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

  本发明涉及治疗慢性关节炎和骨质疏松症的方法，利用已知和新颖化合物，这些化合物可归为以下一般式：（HO）p-A-[-OS（O）.sub.2 NR.sup.1 R.sup.2].sub.z，其中A包括一系列值，包括但不限于芳基，低烷基，环烷基和碳水化合物，包括蔗糖和果糖；p等于分子中未反应的羟基数，可以为零；z是-OS（O）.sub.2 NR.sup.1 R.sup.2基团的数量，始终至少为一；R.sup.1和R.sup.2从氢，低烷基，羧基等中选择；提供了一种新颖的制备该化合物的过程，其中适当的磺酸芳基酯与含有保护羧基，氨基或羟基取代基团的羟基取代A基团在无极溶剂中反应，其中含有三级胺碱。还提供了用于治疗慢性关节炎和骨质疏松症的药物组合物。